News & Updates

In individuals experiencing dyspnoea after sustaining a SARS-CoV-2 infection, physiotherapy, particularly pulmonary rehabilitation, may be beneficial in mitigating respiratory symptoms, according to the results of a systematic review and meta-analysis.

New drug applications approved by US FDA as of 1-15 December 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

In patients with cancer cachexia and elevated levels of growth differentiation factor-15 (GDF-15), GDF-15 inhibition with ponsegromab led to a significant increase in body weight and overall activity level and reduction in cachexia symptoms, a phase II study suggests.

Targeting interleukin-31 signalling with nemolizumab appears to produce substantial improvements in core signs and symptoms of prurigo nodularis (PN), as shown in the phase III OLYMPIA 1 trial.

New research shows limited transmission of the rotavirus vaccine strains in neonatal intensive care units (NICUs), suggesting that the benefits of vaccination outweigh earlier concerns.

Anatomic repair of congenitally corrected transposition of the great arteries (ccTGA), a rare cardiac anomaly, improves overall and reintervention-free survival better than physiologic repair, suggests a recent study.